DHSC updates June 2023 price concessions after CPE members report medicine pricing issues


Share post:

Department of Health and Social Care (DHSC) has updated the final price concessions for June 2023, following a discussion by Community Pharmacy England regarding medicine pricing issues reported by pharmacy owners (its members).

A price concession only applies for the month it is granted; any prices agreed for concessions requested late in the month will roll over into the following month.

Community Pharmacy England encouraged pharmacies to report any problems obtaining a Part VIII product at or below the stated Drug Tariff price, using the online feedback form on the Community Pharmacy England website along with full details of the supplier and price paid for any products sourced above the Drug Tariff price.

The association will investigate the extent of the problem and, if appropriate, discuss the issue with DHSC.

“Since this announcement, we have sent a strong and clear message back to Government that pharmacies cannot continue to subsidise the NHS medicines bill. Following the review of the concessionary price process, a package of measures has been developed to improve the system,” said CPE.

One of the solutions agreed between CPE and DHSC is that from 1st April 2023, all products granted a concessionary price will be classified as ‘Discount Not Deducted’ for the month(s) in which they are on concession.

Furthermore, from May 2023, DHSC has implemented a process to roll over prices to the following month for any concessions requested after the 23rd of the month provided these prices were agreed with us.

CPE is also continuing to work with DHSC on how a ‘retrospective increased payment’ my apply, when appropriate.

Full list below:

Drug Pack size Price concession
* Alginate raft-forming oral suspension sugar free 500 £3.80
Amiloride 5mg tablets 28 £13.46
Amoxicillin 125mg/5ml oral suspension sugar free 100 £2.68
Benzoyl peroxide 5% / Clindamycin 1% gel 60 £22.22
Buprenorphine 8mg sublingual tablets sugar free 7 £11.36
Calamine lotion 200 £1.86
Chloramphenicol 0.5% eye drops 10 £12.51
Chlorphenamine 2mg/5ml oral solution sugar free 150 £4.01
Clotrimazole 500mg pessary and Clotrimazole 2% cream 1 £10.79
Co-careldopa 12.5mg/50mg tablets 90 £4.93
Co-trimoxazole 80mg/400mg tablets 28 £2.34
Docusate 50mg/5ml oral solution sugar free 300 £18.81
Flucloxacillin 250mg capsules 28 £2.45
Isoniazid 100mg tablets 28 £60.00
Ivabradine 5mg tablets 56 £28.33
Letrozole 2.5mg tablets 14 £6.66
Methylphenidate 5mg tablets 30 £3.45
Mometasone 0.1% cream 30 £3.60
Mycophenolate mofetil 500mg tablets 50 £7.69
Pantoprazole 20mg gastro-resistant tablets 28 £6.62
Pantoprazole 40mg gastro-resistant tablets 28 £9.23
Paracetamol 500mg effervescent tablets 100 £10.34
Pregabalin 300mg capsules 56 £4.02
Promethazine hydrochloride 25mg tablets 56 £29.32
Quinine sulfate 200mg tablets 28 £7.97
Risperidone 500microgram tablets 20 £2.98
Rosuvastatin 20mg tablets 28 £4.98
Sodium chloride 0.9% nebuliser liquid 2.5ml unit dose ampoules 20 £11.04
Tacrolimus 0.1% ointment 60 £41.69
Tacrolimus 0.1% ointment 30 £22.36
Tamsulosin 400microgram / Dutasteride 500microgram capsules 30 £14.53
Tolterodine 2mg tablets 56 £3.55
Topiramate 100mg tablets 60 £16.53
Tramadol 37.5mg / Paracetamol 325mg tablets 60 £7.38
Trazodone 50mg capsules 84 £3.45
Venlafaxine 75mg tablets 56 £11.51
Zolmitriptan 2.5mg tablets 6 £18.85
Zolmitriptan 2.5mg tablets 12 £37.70



Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...